2. Immunology/Inflammation
  3. Toll-like Receptor (TLR)
  4. ABR-238901

ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial infarction (MI) research.

For research use only. We do not sell to patients.

CAS No. : 1638200-22-2

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

ABR-238901 Related Antibodies

Top Publications Citing Use of Products

    ABR-238901 purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Jun 4:S2090-1232(25)00391-1.  [Abstract]

    ABR-238901 (30 mg/kg; IP; daily for 7 days) in Six-week-old male BALB/c mice with CVB3-infected (2 × 10^6 pfu/g body weight) significantly reduced the mortality rate in myocarditis mice and partially reversed the mice experienced rapid body weight loss.

    ABR-238901 purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Jun 4:S2090-1232(25)00391-1.  [Abstract]

    ABR-238901 (30 mg/kg; IP; daily for 7 days) in Six-week-old male BALB/c mice with CVB3-infected (2 × 10^6 pfu/g body weight) mitigated the decline in cardiac function caused by viral infection.

    ABR-238901 purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Jun 4:S2090-1232(25)00391-1.  [Abstract]

    ABR-238901 (30 mg/kg; IP; daily for 7 days) in Six-week-old male BALB/c mice with CVB3-infected (2 × 10^6 pfu/g body weight) decreased protein levels of IL-1b, IL-2R, IL-6, IL-10, CXCL2, TNF-a, TGF-b, and NLRP3 in the myocardial tissue.

    ABR-238901 purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Jun 4:S2090-1232(25)00391-1.  [Abstract]

    ABR-238901 (30 mg/kg; IP; daily for 7 days) in Six-week-old male BALB/c mice with CVB3-infected (2 × 10^6 pfu/g body weight) significantly alleviated both inflammatory cell infiltration and the extent of fibrosis. Representative images showing H&E staining of heart sections in four groups.

    ABR-238901 purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 Jun 4:S2090-1232(25)00391-1.  [Abstract]

    ABR-238901 (30 mg/kg; IP; daily for 7 days) in Six-week-old male BALB/c mice with CVB3-infected (2 × 10^6 pfu/g body weight) attenuated the infiltration of neutrophils, monocytes, and macrophages in the heart during viral myocarditis.

    ABR-238901 purchased from MedChemExpress. Usage Cited in: Exp Ther Med. 2022 Apr;23(4):291.

    ABR-238901 (ABR; 30, 50 mg/kg; IP; daily for 3 days) in female Sprague‑Dawley rats withSpinal cord injury increased in both ARB treated groups with that of High‑ARB to show higher MAP2 expression level that of Low‑ARB group.

    ABR-238901 purchased from MedChemExpress. Usage Cited in: Exp Ther Med. 2022 Apr;23(4):291.

    ABR-238901 (ABR; 30, 50 mg/kg; IP; daily for 3 days) in female Sprague‑Dawley rats withSpinal cord injury could effectively promote the expression of NF200 at the lesion area in comparison with the SCI group and High‑ARB could improve the expression of NF200 compared with that in theLow‑ABR.

    ABR-238901 purchased from MedChemExpress. Usage Cited in: Exp Ther Med. 2022 Apr;23(4):291.

    ABR-238901 (ABR; 30, 50 mg/kg; IP; daily for 3 days) in female Sprague‑Dawley rats withSpinal cord injury could inhibit the expression of MPO in the lesion area. MPO expression was notably lower in High‑ARB group than that in Low‑ARB group, suggesting S100A9 blockade might inhibit infiltration by neutrophils.

    ABR-238901 purchased from MedChemExpress. Usage Cited in: Exp Ther Med. 2022 Apr;23(4):291.

    ABR-238901 (ABR; 30, 50 mg/kg; IP; daily for 3 days) in female Sprague‑Dawley rats withSpinal cord injury notably increased the expression levels of the anti‑apoptotic protein, Bcl2 and effectively inhibited the expression level of the pro‑apoptotic proteins, Bax and cleaved caspase‑3. Protein expression level of Bcl2, Bax and cleaved caspase‑3 at the injury site 28 days post‑OR among the groups.

    View All Toll-like Receptor (TLR) Isoform Specific Products:

    View All Isoforms
    TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial infarction (MI) research[1][2][3].

    In Vivo

    ABR-238901 (30 mg/kg/day; gavage; for 3 weeks) causes less angiogenesis and less IL6 and IL10 in MDSCs[1].
    ABR-238901 (30 mg/kg/day; gavage) in combination with Bortezomib (0.6 mg/kg; sc; 2 times/week) reduces tumor load compared with treatments of either agent alone[1].
    ABR-238901 (30 mg/kg; IP for the first 3 d and thereafter continuously p.o.; daily; for 21 days) leads to gradual deterioration of cardiac function and accelerated left ventricular remodeling in C57BL/6NRJ mice with myocardial ischemia induced by permanent coronary artery ligation. Treatment with ABR-238901 during the first 3 days post-myocardial infarction (MI) restricts the inflammatory damage and promotes a reparatory environment[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: C57BL/KaLwRij mice with 5T33MMvv cells[1]
    Dosage: 30 mg/kg
    Administration: Gavage; daily; for 3 weeks
    Result: Caused less angiogenesis. Caused less IL6 and IL10 in myeloid-derived suppressor cells (MDSCs).
    Molecular Weight

    394.63

    Formula

    C11H9BrClN3O4S
    CAS No.
    Appearance

    Solid

    Color

    Off-white to yellow

    SMILES

    O=S(NC1=C(O)C(Cl)=CN=C1)(C2=CN=C(C(Br)=C2)OC)=O
    Shipping

    Room temperature in continental US; may vary elsewhere.
    Storage
    Powder -20°C 3 years
    4°C 2 years
    In solvent -80°C 6 months
    -20°C 1 month
    Solvent & Solubility
    In Vitro: 

    DMSO : 33.33 mg/mL (84.46 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    H2O : < 0.1 mg/mL (insoluble)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 2.5340 mL 12.6701 mL 25.3402 mL
    5 mM 0.5068 mL 2.5340 mL 5.0680 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% Corn Oil

      Solubility: ≥ 2.5 mg/mL (6.34 mM); Clear solution

      This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    % 
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).
    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 98.92%

    SDS (393 KB)

    COA (249 KB) HNMR (262 KB) RP-HPLC (246 KB)

    Handling Instructions (2659 KB)
    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 2.5340 mL 12.6701 mL 25.3402 mL 63.3505 mL
    5 mM 0.5068 mL 2.5340 mL 5.0680 mL 12.6701 mL
    10 mM 0.2534 mL 1.2670 mL 2.5340 mL 6.3350 mL
    15 mM 0.1689 mL 0.8447 mL 1.6893 mL 4.2234 mL
    20 mM 0.1267 mL 0.6335 mL 1.2670 mL 3.1675 mL
    25 mM 0.1014 mL 0.5068 mL 1.0136 mL 2.5340 mL
    30 mM 0.0845 mL 0.4223 mL 0.8447 mL 2.1117 mL
    40 mM 0.0634 mL 0.3168 mL 0.6335 mL 1.5838 mL
    50 mM 0.0507 mL 0.2534 mL 0.5068 mL 1.2670 mL
    60 mM 0.0422 mL 0.2112 mL 0.4223 mL 1.0558 mL
    80 mM 0.0317 mL 0.1584 mL 0.3168 mL 0.7919 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.

    ABR-238901 Related Classifications

    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Keywords:

    ABR-2389011638200-22-2ABR238901ABR 238901Toll-like Receptor (TLR)S100A8/A9RAGETLR4myocardialinfarctionIL6IL10MDSCsInhibitorinhibitorinhibit

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Requested Quantity *

    Applicant Name *

    		 

    Salutation

    Email Address *

    		 

    Phone Number *

    Department

    		 

    Organization Name *

    City

    State

    Country or Region *

    		      

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    ABR-238901
    Cat. No.:
    HY-141537
    Quantity:
    MCE Japan Authorized Agent:

    Customer Review

    Thank You for Your Feedback!

    Request for HNMR Report

    Please fill out this form to request the QC report. We will send it to your Email address shortly.

    Your information is safe with us. * Required Fields.

    Product Name

    		  

    Lot #

    Applicant Name *

    		 

    Email Address *

    Phone Number

    		 

    Department *

    Organization Name *

    		 

    Country or Region *

    Remarks

    SAFETY DATA SHEET (SDS)

    English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Korean - KR (393 KB) Portuguese - PT (393 KB)

    Request for HNMR Report

    We have received your request and will respond to you as soon as possible.